-
Markets
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Navamedic ASA: Invitation to 2025 3rd quarter presentation
24 Oct 2025 17:56 CEST
Issuer
Navamedic ASA
Oslo, October 24, 2025 - Navamedic ASA (OSE: Nava) will be presenting its 3rd
quarter 2025 results on Tuesday, October 28th, 2025. The presentation will be
held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link
to the webcast and the presentation will be available through the Navamedic web
site on the following link: https://navamedic.com/investors/financial-results/
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to
empower people to live healthier and more fulfilling lives. What sets us apart
is our deep-rooted commitment to understanding the needs and requirements of the
countries where we are present. Our local insight and competence enable us to
understand the specific needs of each country where we operate and ultimately to
gain market access. This makes us a preferred partner for international
companies expanding their footprint across the Nordics and Benelux regions,
through either in-licensing or out-licensing. Navamedic has been listed on the
Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo,
Norway. For more information, please visit www.Navamedic.com
More information:
Access the news on Oslo Bors NewsWeb site
Source
Navamedic ASA
Provider
Oslo Børs Newspoint
Company Name
NAVAMEDIC
ISIN
NO0010205966
Symbol
NAVA
Market
Euronext Oslo Børs